Falciparum malaria
Drug research and approvals for falciparum malaria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 20 studies of falciparum malaria are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 1 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 20
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 1
- Management of Severe Plasmodium Falciparum Malaria With Oral Artemisinin DerivativesNCT07935109 · Not reported · Centre Hospitalier de Saint-Denis · starts Jul 15, 2026
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated…NCT07811908 · Phase 2 · Novartis Pharmaceuticals · starts Feb 12, 2026
- Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)NCT07749911 · Not reported · Clinton Health Access Initiative Inc. · starts Jul 14, 2026
- PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in MaliNCT07675785 · Phase 2 · Sanaria Inc. · starts Jul 20, 2026
- First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy AdultsNCT07646353 · Phase 1 · GlaxoSmithKline · starts Jul 27, 2026
- Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated MalariaNCT07559370 · Phase 2 · Victoria Biomedical Research Institute · starts Jan 20, 2026
- A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum MalariaNCT07545681 · Phase 2 · GlaxoSmithKline · starts Oct 7, 2026
- Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug…NCT07389057 · Not applicable · Noguchi Memorial Institute for Medical Research · starts Nov 1, 2023
- Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe AdultsNCT07385287 · Phase 2 · Sanaria Inc. · starts May 4, 2026
Approved 2
- MefloquineFerriprotoporphyrin IX inhibitor
- QuinineFerriprotoporphyrin IX inhibitor
Phase 3 12 of 20
- Artesunate
- ArtemetherFerriprotoporphyrin IX inhibitor
- LumefantrineFerriprotoporphyrin IX inhibitor
- PiperaquineFerriprotoporphyrin IX inhibitor
- ChloroquineFerriprotoporphyrin IX inhibitor
- ArtenimolFerriprotoporphyrin IX binding agent
- PyrimethamineDihydrofolate reductase inhibitor
- SulfadoxineDihydropteroate synthetase inhibitor
- AzithromycinBacterial 70S ribosome inhibitor
- AmodiaquineFerriprotoporphyrin IX inhibitor
- Primaquine
- Lumefantrine co-artemether
Phase 2 12 of 13
- Rabies vaccineBiological vaccine - induces immune response
- MATRIX-M1 adjuvant
- Tafenoquine
- Artefenomel
- Methylene blue cationReducing agent
- ImatinibTyrosine-protein kinase ABL inhibitor
- CipargaminP-type ATPase inhibitor
- Ganaplacide
- PentoxifyllineAdenosine A2 receptor antagonist
- Fosmidomycin1-deoxy-D-xylulose 5-phosphate reductoisomerase, apicoplastic inhibitor
- DSM-265Dihydroorotate dehydrogenase inhibitor
- Arginine hydrochloride
Phase 1 or earlier 7
- Aluminum hydroxideAntacid
- MMV-048
- RosiglitazonePeroxisome proliferator-activated receptor gamma agonist
- Nitrous acid
- Aluminum phosphate
- ImiquimodToll-like receptor 7 agonist
- Yellow fever vaccineBiological vaccine - induces immune response
How its trials ended
338 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 140 whose ending is known, 63% met their primary endpoint, 14% missed it and 24% stopped early.
- Completed, result not reported13741%
- Met its primary endpoint8826%
- Ongoing3410%
- Status unknown278%
- Stopped: other or unclear237%
- Missed its primary endpoint196%
- Stopped: lack of efficacy31%
- Stopped: sponsor or business decision31%
- Stopped: funding21%
- Stopped: safety1<1%
- Stopped: enrollment or feasibility1<1%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Aug 12, 2005 | Quinine SulfateTreatment of uncomplicated Plasmodium falciparum malaria | AR Holding Company, Inc. | Approved |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Oct 27, 2011 | EurartesimPiperaquine tetraphosphate; artenimol | Alfasigma S.p.A. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA